Notably, GLP-1RAs slow the transit time of the gastrointestinal (GI) tract and suppress appetite, which could displace nutrient intake and result in mineral and vitamin deficiencies
Patient ratings carry the most weight, followed by the number of verified reviews, provider credentials (including ABOM board certification in obesity medicine), and verification level
Nature Medicine (2024) 4
doi: 10.1056/NEJMoa1506930 259 DoehnerWErdmannECairnsRClarkALDormandyJAFerranniniEet al
Semaglutide Semaglutide was designed as a potent, long-acting GLP-1 analogue that could be administered subcutaneously (s.c.) once weekly, rather than s.c
First published in February 1922, their results were heralded as a major achievement and transformed the treatment of diabetes (Diem, Ducluzeau, Scheen